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background: It is necessary to identify which hypertrophic cardiomyopathy (HCM) patients are most likely to harbor pathogenic mutations so 
providers better understand the sensitivity of genetic testing in this patient population.
Methods: HCM patients underwent clinical evaluations to confirm their diagnosis, and a 3-generation pedigree was constructed. Index HCM 
patients underwent genetic testing for mutations in HCM associated myofilament genes and glycogen storage cardiomyopathy genes.
results: In 89 unrelated HCM patients, 65 (73%) carried a mutation in a myofilament gene (60% MYBPC3, 27% MYH7, 9% TNNT2, 3% TNNI3, 1% 
MYL2). No patients tested positive for mutations in glycogen storage genes (PRKAG2, GLA, LAMP2). There were 24 HCM patients in whom genetic 
testing was negative. HCM patients with a positive family history of disease (FH+) had a 90% (45/50) chance of harboring a myofilament mutation 
regardless of age (median age 40) (45/50 FH+,mutation+ vs. 20/39 FH-,mutation+; p<0.0001). In the patients with no family history of HCM and 
age less than 40, the likelihood of harboring a myofilament mutation was 87% (13/15). In contrast, only 29% (7/24) of HCM patients > 40yo with 
no family history of HCM were mutation carriers (Fig 1).
conclusion: We discovered that a family history of HCM and age less than 40 were predictors of increased genetic testing sensitivity in HCM 
patients. This information can be utilized by clinicians and HCM patients to make more informed decisions regarding genetic testing.
 
